Increased risk of hepatoblastoma among immature children with a lower birth weight

M Tanimura1, I Matsui, J Abe

  • 1Department of Child Ecology, National Children's Medical Research Center, Tokyo, Japan.

Cancer Research
|July 29, 1998
PubMed

Insights

Hepatoblastoma risk increases with lower birth weight, especially for infants under 1000g. Recent increases in childhood hepatoblastoma may stem from improved survival of very low birth weight infants and perinatal care factors.

Area of Science:

  • Pediatric Oncology
  • Perinatal Medicine
  • Epidemiology

Background:

  • Hepatoblastoma incidence has risen in very low birth weight infants.
  • A potential link between low birth weight and hepatoblastoma requires investigation.

Purpose of the Study:

  • To clarify the relationship between low birth weight and hepatoblastoma risk.
  • To analyze trends in hepatoblastoma incidence among low birth weight infants in Japan.

Main Methods:

  • Comparative analysis of hepatoblastoma cases and live births in Japan (1969-1994).
  • Stratification by birth weight categories and birth year periods.
  • Calculation of relative risks for hepatoblastoma based on birth weight.

Main Results:

  • Hepatoblastoma patients showed higher percentages in birth weight categories of 1500-1999g and 2000-2499g compared to the general live birth population.
  • A significant increase in hepatoblastoma cases with birth weights <1500g and <1000g was observed after 1988.
  • Relative risk of hepatoblastoma was highest for birth weights <1000g (15.64), followed by 1500-1999g (2.71) and 1000-1499g (2.53), compared to birth weights ≥2500g.

Conclusions:

  • Lower birth weight is associated with a significantly higher risk of hepatoblastoma.
  • The recent increase in hepatoblastoma may be attributed to increased survival of extremely premature infants and perinatal care practices.
  • No association found between low birth weight hepatoblastoma and congenital malformations or small-for-date status.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...